Research on Lipodystrophy & Other Metabolic Complications

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

2003 | 2002 | 2001 | 1997-2000

See also: Lipodystrophy Basics

2002

Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Cost-Effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults (November 25, 2002)
A study asserts that, generally speaking, the risks of lipodystrophy and heart disease are outweighed by the benefits of early HIV treatment.
In Archives of Internal Medicine
National Institutes of Health Awards $1.95 Million to Study New Treatments for Drug Side Effects (November 22, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Metabolic Toxicities and HIV (November/December 2002)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Study Reports Self-Image Concerns in HIV-Positive People With Lipodystrophy (October 22, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Insulin Resistance and HIV-Related Lipoatrophy (October 9, 2002)
Dr. Nasser Mikhail attempts to explain recent study findings.
In Journal of the American Medical Association
HIV Positive May Risk Death to Avoid Side Effect of Meds (October 2, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Case Against Zerit (October 2002)
Research increasingly points to NRTIs -- particularly d4T -- as a likely culprit in metabolic disorders.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Overview of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
The Viramune Hepatic Safety Project: Analysis of Symptomatic Hepatic Events (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Twelve Weeks of Atazanavir Treatment Reverses Nelfinavir-Associated Hyperlipidemia: Results From BMS AI424-044 (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
The Mechanisms of Lipodystrophy: Leptin, Lipodystrophy and Insulin Resistance; Treatment of Non-HIV Lipodystrophy With Thiazolidinediones and Leptin (September 23, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Cancer Drug for Male Breast Enlargement? (September 18, 2002)
From Canadian AIDS Treatment Information Exchange
Lactic Acidosis: Watching and Waiting (September 2002)
Metformin (glucophage), used to treat diabetes, may add to the lactic acidosis risk posed by some antiretrovirals.
In HIV Treatment ALERTS!, from The Center for AIDS
Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir, Efavirenz or Nevirapine; Twelve-Month Results of a Randomized Study (LIPNEFA) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy (July 10, 2002)
In Journal of the American Medical Association
Fat Redistribution and Metabolic Changes With a Nucleoside-Reverse Transcriptase Inhibitor, Non-NRTI, or Protease Inhibitor-Based Regimen: FRAMS Substudy of the Atlantic Study (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Disturbing Metabolic Disturbances: Basic Science (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Disturbing Metabolic Disturbances: Clinical Impact (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Quantification of Mitochondrial DNA in Human Cells Using Real-Time PCR With Fluorogenic Reporters (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Special Retrovirus Update: Lipodystrophy (March 28, 2002)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
Lipoatrophy and Antiretroviral Drug Changes (March 8, 2002)
In AIDS Treatment News, from AIDS Treatment News
9th Retrovirus Conference Coverage: Lipodystrophy Definition (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project
9th Retrovirus Conference Coverage: Lipodystrophy Treatment (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project
9th Retrovirus Conference Coverage: Lipodystrophy: To Switch or Not to Switch? (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project
Lipodystrophy Update (March 2002)
To read PDF, click here
In Project Inform Perspective, from Project Inform
A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.